Skip to main content
SpringerLink
Log in

Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 17 June 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Noguchi Y. Comment on “Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data”. Drug Saf. 2022. https://doi.org/10.1007/s40264-022-01191-2

  2. Alkabbani W, Pelletier R, Beazely MA, Labib Y, Quan B, Gamble JM. Drug-drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data. Drug Saf. 2022;45:287–95.

    Article  CAS  Google Scholar 

  3. Noren GN, Sundberg R, Bate A, Edwards IR. A statistical methodology for drug-drug interaction surveillance. Stat Med. 2008;27:3057–70.

    Article  Google Scholar 

  4. Noguchi Y, Tachi T, Teramachi H. Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems. Pharm Res. 2020;37:86.

    Article  CAS  Google Scholar 

  5. Thakrar B, Grundschober SB, Doessegger L. Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol. 2007;64:489–95.

    Article  CAS  Google Scholar 

  6. Strandell J, Caster O, Hopstandius J, Edwards IR, Noren GK. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Saf. 2013;36:371–88.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, Faculty of Science, University of Waterloo, 10A Victoria Street S., Kitchener, ON, N2G1C5, Canada

    John-Michael Gamble & Wajd Alkabbani

Authors
  1. John-Michael Gamble
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wajd Alkabbani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John-Michael Gamble.

Ethics declarations

Funding

No direct funding was received for this project.

Conflict of interest

John-Michael Gamble and Wajd Alkabbani declare that they have no potential conflicts of interest that might be relevant to the contents of this letter.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Authors contribution

All authors contributed to the preparation of the letter and read and approved the final version.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gamble, JM., Alkabbani, W. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”. Drug Saf 45, 813–814 (2022). https://doi.org/10.1007/s40264-022-01192-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-022-01192-1

Search

Navigation